news

  • 4 April 2018
    Arsanis Out-Licenses Preclinical Stage E. coli Monoclonal Antibodies

    Arsanis, Inc. (NASDAQ: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced that it has entered into an agreement under which BB100, LLChas secured an exclusive, worldwide preclinical development license, and an option to a clinical development and commercialization license, to monoclonal antibodies (mAbs) targeting E. coli that were discovered by Arsanis in its ASN200 program.

    “This transaction allows Arsanis to continue the focused execution of our ongoing ASN100 Phase 2 clinical trial while providing for the potential advancement of our novel, multi-modal mAbs targeting E. coli, a leading cause of serious hospital infections,” said René Russo, chief executive officer of Arsanis. “We are pleased to place these mAbs in the hands of BB100, a subsidiary of Bravos Bioscience, LLC, led by Dr. Paul Ambrose and a leadership team that is globally recognized as a leader in anti-infective drug development and has played a critical role in the development and approval of many anti-infectives developed over the last decade.”

    Under the agreement, Arsanis has granted BB100 the exclusive right to conduct further preclinical development activities on licensed mAbs, with an option to enter into an exclusive global development and commercial license.